CG Oncology, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CG Oncology, Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $2.06M, a 10747.37% increase year-over-year.
- CG Oncology, Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $1.50M, a 119.21% increase year-over-year.
- CG Oncology, Inc. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $5.10M, a 135.30% increase year-over-year.
- CG Oncology, Inc. stock issued during period, value, new issues for the quarter ending 2025-06-30 was $19.00K, a 75.32% decline year-over-year.
- CG Oncology, Inc. stock issued during period, value, new issues for fiscal 2025 was $6.46M, a 148.40% increase from fiscal 2024.
- CG Oncology, Inc. stock issued during period, value, new issues for fiscal 2024 was $2.60M, a 24.83% increase from fiscal 2023.
- CG Oncology, Inc. stock issued during period, value, new issues for fiscal 2023 was $2.08M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $2.06M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $1.50M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $6.46M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $5.10M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $19.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $682.00K 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $2.60M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $2.17M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $77.00K 10-Q · filed 2025-11-14 | |
| 2024-03-31 | $399.56M 10-Q · filed 2025-11-14 | |
| 2023-12-31 | $2.08M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $1.59M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $165.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $68.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |